David Lawrence Flanigan

Title: David Lawrence Flanigan: Innovator in Target Binding Molecules

Introduction

David Lawrence Flanigan is a notable inventor based in Riverview, FL (US). He holds a total of 4 patents that contribute significantly to the field of molecular synthesis and pharmaceutical formulations. His work focuses on innovative methods for identifying target binding molecules, which have important applications in medical research and drug development.

Latest Patents

One of Flanigan's latest patents is titled "Target binding molecules identified by kinetic target-guided synthesis." This patent outlines methods for identifying target binding molecules that can bind to proteins or nucleic acids. The methods involve mixing two or more reactive fragments with a target, allowing for the identification of molecules that bind to shallow binding pockets on the surface of targets such as the Bcl-XL and Mcl-1 proteins. Additionally, he has developed pharmaceutical formulations of these target binding molecules, enhancing their potential therapeutic applications.

Another significant patent describes quinazoline-based compounds and their formulations. These compounds are designed to inhibit and kill specific targets, providing new avenues for treatment. The methods outlined in this patent involve administering these compounds to subjects in need, showcasing Flanigan's commitment to advancing medical science.

Career Highlights

Flanigan has had a distinguished career, working with reputable organizations such as the University of South Florida and Medicines for Malaria Venture. His contributions to these institutions have been instrumental in furthering research and development in the field of pharmaceuticals.

Collaborations

Throughout his career, Flanigan has collaborated with esteemed colleagues, including Roman Manetsch and Michael Kevin Riscoe. These partnerships have fostered innovation and have led to significant advancements in their respective fields.

Conclusion

David Lawrence Flanigan is a prominent inventor whose work in target binding molecules and quinazoline-based compounds has made a lasting impact on pharmaceutical research. His innovative approaches and collaborations continue to drive advancements in medical science.